Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
Demo Company

Recombinant Poultry Virus Selectively Kills Human Prostate Cancer Cells

By BiotechDaily International staff writers
Posted on 05 Mar 2013
A recombinant form of the Newcastle disease virus (NDV) that replicates in humans only in the presence of prostate specific antigen (PSA) was found to kill prostate cancer cells, including hormone resistant cells, without damaging normal tissues.

Newcastle disease is a contagious bird disease affecting many domestic and wild avian species. The virus has a negative-sense, single-stranded genome that codes for a RNA-directed RNA polymerase, hemagglutinin-neuraminidase protein, fusion (F) protein, matrix protein, phosphoprotein, and nucleoprotein in the 5' to 3' direction. Its effects are most notable in domestic poultry due to their high susceptibility and the potential for severe impacts of an epizootic on the poultry industries. Exposure of humans to infected birds can cause mild conjunctivitis and influenza-like symptoms, but NDV otherwise poses no hazard to human health. Interest in the use of NDV as an anticancer agent has arisen from the ability of NDV to selectively kill human tumor cells with limited toxicity to normal cells. However, systemically delivered NDV fails to reach solid tumors in therapeutic concentration and also spreads poorly within the tumors due to barriers including complement, innate immunity, and extracellular matrix.

Investigators at the Virginia Polytechnic Institute (Blacksburg, USA) created a novel recombinant form of NDV in which the F protein was cleavable exclusively by human PSA.

They reported in the January 23, 2013, online edition of the Journal of Virology that the recombinant NDV replicated efficiently and specifically in prostate cancer (CaP) cells and three-dimensional prostaspheres but failed to replicate in the absence of PSA. Furthermore, PSA-cleavable recombinant NDV caused specific lysis of androgen independent and androgen responsive/nonresponsive CaP cells and prostaspheres. PSA-cleavable NDV failed to replicate in chicken embryos, indicating no pathogenicity to chickens.

"Retargeted Newcastle disease virus has major potential advantages over other cancer therapies," said senior author Dr. Subbiah Elankumaran, associate professor of virology at Virginia Polytechnic Institute. "First, its specificity for prostate cancer cells means it would not attack normal cells, thereby avoiding the various unpleasant side effects of conventional chemotherapies. In previous clinical trials, even with extremely large doses of naturally occurring strains, only mild flu-like symptoms were seen in cancer patients. Second, it would provide a new treatment for hormone-refractory patients, without the side effects of testosterone suppression that result from hormonal treatments."

Related Links:
Virginia Polytechnic Institute



Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.